Director/PDMR Shareholding
Updated : 11:52
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
6 April 2022
Graft Polymer (UK) Plc
("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")
Director/PDMR Shareholding
The Company was notified today that on 31 March 2022, Freya Holdings Limited, an entity entirely owned and controlled by Roby Zomer, Non-executive Chairman of the Company, transferred its entire shareholding in Graft Polymer (totalling 4,576,163 ordinary shares of £0.001 each ("Ordinary Shares")) to Chitta Lu Limited, which Mr. Zomer also entirely owns and controls. Roby Zomer remains the beneficial holder of these Ordinary Shares. The same lock-in arrangements apply to the Ordinary Shares as applied prior to such transfer.
----- END -----
For more information, please visit https://www.graftpolymer.com or contact:
Graft Polymer (UK) Plc | via Tavistock |
Roby Zomer, Chairman | |
Yifat Steuer, CFO | |
| |
Turner Pope Investments (Broker) | +44 20 3657 0050 |
James Pope | |
Andy Thacker | |
Tavistock (Public Relations) | +44 207 920 3150 |
Heather Armstrong | graftpolymer@tavistock.co.uk |
Katie Hopkins |
About Graft Polymer
Graft Polymer is a UK incorporated holding company with an innovative research and manufacturing facility, based in Slovenia. The core business of the Group comprises polymer modification and drug delivery systems developments. Established in 2017, the Group has already introduced more than 50 products to the market.
The Group has developed a proprietary set of polymer modification technologies, which can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.
In particular, the Group's techniques allow the combination of otherwise incompatible polymers, facilitating the creation of polymer composites engineered at a molecular level, that combine the attractive properties of different input materials. This enables customers to receive a synergism of properties in polymer composites.
The solutions and products offered by the Group are designed to improve performance, reduce raw materials consumption, and enhance the physical characteristic values of finished products or improve or modify their chemical interaction. In the past several years, there has been increased emphasis by the industry as a whole on applications of grafted polymers, which are produced by monomers being covalently bonded and polymerised as side chains onto the main polymer chain (the backbone).
In 2020, the Group launched a new division named GraftBio to develop IP for Bio/Pharma applications. This includes a drug delivery system to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic. The GraftBio division is in the process of obtaining the HACCP certification for its production facility. The Group has developed a set of drug delivery platforms that enable it to licence its DDS platform (IP) to MGC Pharmaceuticals Limited ("MGC"; LSE: MXC) in relation to MGC's CimetrA™ and CannEpil-IL™ products. The Group expects to receive royalty payments resulting from the sale by MGC of CimetrA™ and CannEpil-IL™ products.
PDMR Disclosures
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Roby Zomer | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Non-executive Chairman | ||||
b) | Initial notification/amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Graft Polymer (UK) plc | ||||
b) | LEI | 2138005PH7OJRCRPUD88 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of £0.001 each ("Ordinary Shares") | ||||
Identification code | GB00BN92HZ16 | |||||
b) | Nature of the Transaction | Transfer of Ordinary Shares in the Company | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A | ||||
e) | Date of the transaction | [XX] March 2022 | ||||
f) | Place of the transaction | Standard Segment of the London Stock Exchange |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.